The Experts below are selected from a list of 50853 Experts worldwide ranked by ideXlab platform
Eduardo Bruera - One of the best experts on this subject based on the ideXlab platform.
-
Transcultural Validation of the French Version of the Modified Edmonton Symptom Assessment Scale: The ESAS12-F.
Journal of palliative medicine, 2019Co-Authors: Colombe Tricou, Eduardo Bruera, Cheryl Nekolaichuk, Murielle Ruer, Katrin Ruth Sigurdardottir, Élise Perceau-chambard, Marilène FilbetAbstract:Abstract Background: Cancer-related physical Symptoms can decrease patients' overall quality of life and are often underdiagnosed. The Edmonton Symptom Assessment Scale (ESAS) is widely used in pal...
-
A simple system for Symptom Assessment in pediatric palliative care patients with cancer: A preliminary report.
Journal of Clinical Oncology, 2018Co-Authors: Kevin Madden, Maira Charone, Seyedeh Dibaj, Sarah Mills, Janet L. Williams, Diane D. Liu, Eduardo BrueraAbstract:81Background: Systematic Symptom Assessment is not a standard of care in children with cancer. Many well-known Symptom Assessment tools are lengthy or difficult to integrate into a daily pediatric palliative care practice. We created a series of brief and simple questions to be systematically given to children and their caregivers. The primary objective was to determine the percentage of eligible children and caregivers exposed to the questions that were able to complete the Assessment. Secondary objectives included documenting the Symptom burden at time of consultation, evaluating the level of agreement in Symptom reporting between children and caregivers, as well as between children/caregivers and the referring medical team. Methods: A series of systematic questions were presented to all caregivers (if present) and children who were 7 years of age or older at time of initial consultation with pediatric palliative care. Results: 122 consecutive children and caregivers were given the survey. 107/108 (99%)...
-
The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments.
Journal of pain and symptom management, 2016Co-Authors: David Hui, Eduardo BrueraAbstract:Abstract Context Routine Symptom Assessment represents the cornerstone of Symptom management. Edmonton Symptom Assessment System (ESAS) is one of the first quantitative Symptom Assessment batteries that allows for simple and rapid documentation of multiple patient-reported Symptoms at the same time. Objectives To discuss the historical development of ESAS, its current uses in different settings, and future developments. Methods Narrative review. Results Since its development in 1991, ESAS has been psychometrically validated and translated into over 20 languages. We will discuss the variations, advantages, and limitations with ESAS. From the clinical perspective, ESAS is now commonly used for Symptom screening and longitudinal monitoring in patients seen by palliative care, oncology, nephrology, and other disciplines in both inpatient and outpatient settings. From the research perspective, ESAS has offered important insights into the nature of Symptom trajectory, Symptom clusters, and Symptom modulators. Furthermore, multiple clinical studies have incorporated ESAS as a study outcome and documented the impact of various interventions on Symptom burden. On the horizon, multiple groups are actively investigating further refinements to ESAS, such as incorporating it in electronic health records, using ESAS as a trigger for palliative care referral, and coupling ESAS with personalized Symptom goals to optimize Symptom response Assessment. Conclusion ESAS has evolved over the past 25 years to become an important Symptom Assessment instrument in both clinical practice and research. Future efforts are needed to standardize this tool and explore its full potential to support Symptom management.
-
Psychometric Validation of the Edmonton Symptom Assessment System in Chinese Patients.
Journal of pain and symptom management, 2015Co-Authors: Yixue Dong, Heng Chen, Yuanyu Zheng, Ying Guo, Jung Hye Kwon, En Liu, Hong Guo, Eduardo BrueraAbstract:Abstract Context The Edmonton Symptom Assessment System is a simple and widely used questionnaire to assess patient Symptoms. Objectives We aimed to develop and verify a Chinese version of the Edmonton Symptom Assessment System (C-ESAS) for use with Chinese patients. Methods Two hundred ten patients were surveyed in the Department of Gastroenterology of Xinqiao hospital in southwest China. Patients completed the C-ESAS and the Chinese version of the M. D. Anderson Symptom Inventory to assess internal consistency, test-retest reliability, and concurrent validity of the C-ESAS. The questionnaires were completed again two hours later. Results The C-ESAS demonstrated acceptable internal consistency (Cronbach α = 0.72). This indicated that no question had an inappropriate effect on the score. Pearson correlation coefficients for the C-ESAS Symptom scores between baseline and after two hours ranged from 0.47 (95% CI, 0.35–0.89) to 0.92 (95% CI, 0.57–0.94), indicating strong test-retest reliability. The corresponding Chinese version of the M. D. Anderson Symptom Inventory Symptom scores ranged from 0.66 (95% CI, 0.58–0.95) to 0.96 (95% CI, 0.73–0.97), indicating good concurrent validity. The average time to complete the C-ESAS differed according to patient education level. Conclusion The C-ESAS is a good tool for measuring multidimensional Symptoms in Chinese patients.
-
the brazilian version of the edmonton Symptom Assessment system esas is a feasible valid and reliable instrument for the measurement of Symptoms in advanced cancer patients
PLOS ONE, 2015Co-Authors: Carlos Eduardo Paiva, David Hui, Luciana Lopes Manfredini, Bianca Sakamoto Ribeiro Paiva, Eduardo BrueraAbstract:Purposes To develop and validate a Portuguese version of the Edmonton Symptom Assessment System (ESAS) in Brazilian patients with advanced cancer.
Victor T. Chang - One of the best experts on this subject based on the ideXlab platform.
-
Validation of the Simplified Chinese Version of the Memorial Symptom Assessment Scale-Short Form Among Cancer Patients.
Journal of pain and symptom management, 2018Co-Authors: Yingfeng Zhou, Victor T. Chang, Xiaoju Zhang, Yang Yang, Yang WangAbstract:Abstract Context Comprehensive Symptom Assessment is crucial for Symptom management. The Memorial Symptom Assessment Scale—Short Form (MSAS-SF) has been validated for Symptom Assessment in cancer patients, but there is no simplified Chinese version. Objectives To present the validation procedures and results for the simplified Chinese version of the Memorial Symptom Assessment Scale—Short Form (MSAS-SF-SC) among cancer patients in mainland China. Methods The MSAS-SF was translated and culturally adapted into simplified Chinese. About 359 cancer patients completed the MSAS-SF-SC, the Chinese Functional Assessment of Cancer Therapy—General, the Chinese Brief Fatigue Inventory, the Chinese Hospital Anxiety and Depression Scale, and the Chinese Medical Outcomes Study Social Support Survey. Reliability was assessed by internal consistency and test-retest coefficients. Convergent and divergent validity were analyzed by Pearson's correlation coefficients between MSAS-SF-SC subscales and the other instruments. Known-groups validity used Eastern Cooperative Oncology Group—Performance Status, hemoglobin level, and primary site. Results The MSAS-SF-SC was reliable with Cronbach's alpha coefficients for subscales ranging from 0.782 to 0.874 and test-retest coefficients ranging from 0.819 to 0.872. MSAS-SF-SC subscales correlated with corresponding Chinese Functional Assessment of Cancer Therapy—General subscales (−0.557 to −0.680; P Conclusion The MSAS-SF-SC demonstrated good psychometric properties and is culturally adapted. The instrument could be a valuable tool for Chinese health care professionals and researchers.
-
Reliability and Validity of the Korean Memorial Symptom Assessment Scale-Short Form in Gynecological Cancer Patients.
Journal of pain and symptom management, 2017Co-Authors: Ju-hee Nho, Victor T. Chang, Sung Reul Kim, Joo-hyun NamAbstract:Abstract Context Symptoms of patients with cancer need to be evaluated with a standard instrument. The Memorial Symptom Assessment Scale-Short Form (MSAS-SF) is a Symptom Assessment tool that has been validated in many languages. Objectives The aim of the present study was to validate the Korean-version Memorial Symptom Assessment Scale—Short Form (MSAS-SF) in patients with gynecologic cancer. Methods We translated the MSAS-SF into Korean, and 175 gynecologic cancer inpatients completed the MSAS-SF, Functional Assessment Cancer Therapy—General (FACT-G), and gathered demographic and clinical data and Karnofsky Performance Status (KPS). Reliability was assessed for internal consistency with Cronbach's alpha coefficient. Pearson's correlation coefficient was calculated between the MSAS-SF and FACT-G subscales for convergent validity. T-test analysis was used to compare differences in MSAS-SF subscales by cancer stage and KPS for discriminant validity. Results The Cronbach's alpha coefficients for the MSAS-SF subscales ranged from 0.80 to 0.91. The Korean-version MSAS-SF subscales showed convergent validity with FACT-G subscales. The correlation coefficients were −0.640 (P Conclusion The Korean-version MSAS-SF is a valid tool for the reliable Assessment of patients with gynecologic cancer in Korea.
-
New insights in Symptom Assessment: the Chinese Versions of the Memorial Symptom Assessment Scale Short Form (MSAS-SF) and the Condensed MSAS (CMSAS).
Journal of pain and symptom management, 2008Co-Authors: Wendy W. T. Lam, Victor T. Chang, Chi Ching Law, Kh Wong, Richard FieldingAbstract:There are very few Symptom Assessment instruments in Chinese. We present the validity and reliability of the Memorial Symptom Assessment Scale Short Form (MSAS-SF) and the Condensed Form MSAS (CMSAS) in Chinese cancer patients. The Chinese version of the 32-item MSAS-SF, a self-report measure for assessing Symptom distress and frequency in cancer patients, was administered to 256 Chinese patients with colorectal cancer at a clinical oncology outpatient unit. Highly prevalent Symptoms included worrying (59%), dry mouth (54%), lack of energy (54%), feeling sad (48%), feeling irritable (48%), and pain (41%). Both the MSAS-SF and CMSAS demonstrated good validity and reliability. For the MSAS-SF subscales, Cronbach alphas ranged from 0.84 to 0.91, and for CMSAS subscales, from 0.79 to 0.87. Moderate-to-high correlations of MSAS-SF and CMSAS subscales with appropriate European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 subscales (0.42-0.71, Ps or =80% [P 4 [P
-
Shorter Symptom Assessment Instruments: The Condensed Memorial Symptom Assessment Scale (CMSAS)
Cancer investigation, 2004Co-Authors: Victor T. Chang, Shirley S. Hwang, Basil Kasimis, Howard T. ThalerAbstract:Background. Rapid and efficient Symptom Assessment is an important aspect of palliative care. The objective was to determine whether a smaller number of Symptoms from the 32-item Memorial Symptom Assessment Scale Short-Form (MSAS-SF) could convey equivalent quality of life (QOL) information. Methods. Responses from 479 medical oncology patients who completed the MSAS-SF and the Functional Assessment Cancer Therapy (FACT-G) were analyzed. Canonical correlations were performed to assess the relationships of 32 MSAS-SF Symptoms to quality of life (FACT-G domains) and clinical variables [age, Karnofsky performance status (KPS), stage of disease, and inpatient status]. The relation of the subscales of the Condensed MSAS (CMSAS) and FACT-G to survival was assessed in a multivariate model. Results. The median age was 67 years (range, 20–89) and median KPS was 80% (range, 20–100). Primary sites were prostate in 141 (29%) patients, lung in 121 (26%) patients, colorectal in 53 (11%) patients, hematologic in 50 (10%...
-
Memorial Symptom Assessment Scale
Expert review of pharmacoeconomics & outcomes research, 2004Co-Authors: Victor T. Chang, Shirley S. Hwang, Howard T. Thaler, Basil Kasimis, Russell K. PortenoyAbstract:Patients with advanced illnesses often have multiple Symptoms. As interest in palliative care and interventions for Symptom control increase, the ability to assess multiple Symptoms has become more important. A number of instruments have been developed to meet this need in cancer patients. This article reviews the development and applications of a multidimensional instrument, the Memorial Symptom Assessment Scale. The Memorial Symptom Assessment Scale has 32 Symptoms and three dimensions of frequency, severity, and distress. Shorter versions – The Memorial Symptom Assessment Scale Short Form (32 Symptoms with one dimension) and the Condensed Memorial Symptom Assessment Scale (14 Symptoms with one dimension), and a version for children aged 7–12 years, have also been developed. A distinctive feature is the summary subscales for physical distress, psychological distress, and The Global Distress Index. The Memorial Symptom Assessment Scale has proven useful in description of Symptom epidemiology, the role of...
Howard T. Thaler - One of the best experts on this subject based on the ideXlab platform.
-
Shorter Symptom Assessment Instruments: The Condensed Memorial Symptom Assessment Scale (CMSAS)
Cancer investigation, 2004Co-Authors: Victor T. Chang, Shirley S. Hwang, Basil Kasimis, Howard T. ThalerAbstract:Background. Rapid and efficient Symptom Assessment is an important aspect of palliative care. The objective was to determine whether a smaller number of Symptoms from the 32-item Memorial Symptom Assessment Scale Short-Form (MSAS-SF) could convey equivalent quality of life (QOL) information. Methods. Responses from 479 medical oncology patients who completed the MSAS-SF and the Functional Assessment Cancer Therapy (FACT-G) were analyzed. Canonical correlations were performed to assess the relationships of 32 MSAS-SF Symptoms to quality of life (FACT-G domains) and clinical variables [age, Karnofsky performance status (KPS), stage of disease, and inpatient status]. The relation of the subscales of the Condensed MSAS (CMSAS) and FACT-G to survival was assessed in a multivariate model. Results. The median age was 67 years (range, 20–89) and median KPS was 80% (range, 20–100). Primary sites were prostate in 141 (29%) patients, lung in 121 (26%) patients, colorectal in 53 (11%) patients, hematologic in 50 (10%...
-
Memorial Symptom Assessment Scale
Expert review of pharmacoeconomics & outcomes research, 2004Co-Authors: Victor T. Chang, Shirley S. Hwang, Howard T. Thaler, Basil Kasimis, Russell K. PortenoyAbstract:Patients with advanced illnesses often have multiple Symptoms. As interest in palliative care and interventions for Symptom control increase, the ability to assess multiple Symptoms has become more important. A number of instruments have been developed to meet this need in cancer patients. This article reviews the development and applications of a multidimensional instrument, the Memorial Symptom Assessment Scale. The Memorial Symptom Assessment Scale has 32 Symptoms and three dimensions of frequency, severity, and distress. Shorter versions – The Memorial Symptom Assessment Scale Short Form (32 Symptoms with one dimension) and the Condensed Memorial Symptom Assessment Scale (14 Symptoms with one dimension), and a version for children aged 7–12 years, have also been developed. A distinctive feature is the summary subscales for physical distress, psychological distress, and The Global Distress Index. The Memorial Symptom Assessment Scale has proven useful in description of Symptom epidemiology, the role of...
-
The Measurement of Symptoms in Young Children With Cancer: The Validation of the Memorial Symptom Assessment Scale in Children Aged 7–12
Journal of pain and symptom management, 2002Co-Authors: John J. Collins, Howard T. Thaler, Tom D Devine, Gina S Dick, Elizabeth A Johnson, Henry Kilham, C.ross Pinkerton, M.m Stevens, Russell K. PortenoyAbstract:Few studies have attempted to describe the experience of Symptoms in young children with cancer. This is due, in part, to the lack of validated Symptom Assessment scales for this patient population. The objective of this study was to evaluate the reliability and validity of a revised Memorial Symptom Assessment Scale (MSAS) in patients aged 7-12 as an instrument for the Assessment of Symptoms in young children with cancer. The MSAS (7-12) was administered to 149 children (inpatients and outpatients) who were undergoing treatment at either the Royal Marsden NHS Trust, London, United Kingdom or The Children's Hospital at Westmead, Sydney, Australia. Validity was evaluated by comparison with the medical record, parental report, and concurrent Assessment on visual analogue scales for selected Symptoms. The data provide evidence of the reliability and validity of MSAS (7-12) and demonstrate that children with cancer as young as 7 years can report clinically relevant and consistent information about their Symptom experience. Young children with cancer experience multiple Symptoms. Approximately one-third had experienced lethargy and/or pain and/or insomnia during the 48 hours prior to the completion of MSAS (7-12). The completion rate for MSAS (7-12) was high and the majority of children completed the instrument in a short period of time and with little difficulty. The instrument appears to be age appropriate and may be helpful to older children unable to independently complete MSAS (10-18). Systematic Symptom Assessment may be useful in future epidemiological studies of Symptoms and in cancer chemotherapy drug trials.
-
The Memorial Symptom Assessment Scale Short Form (MSAS‐SF)
Cancer, 2000Co-Authors: Victor T. Chang, Shirley S. Hwang, Basil Kasimis, Martin Feuerman, Howard T. ThalerAbstract:BACKGROUND The Memorial Symptom Assessment Scale Short Form (MSAS-SF), an abbreviated version of the Memorial Symptom Assessment Scale, measures each of 32 Symptoms with respect to distress or frequency alone. A physical Symptom subscale (PHYS), psychologic Symptom subscale (PSYCH), and global distress index (GDI) can be derived from the Short Form. We validated the MSAS-SF in a population of cancer patients. METHODS Two hundred ninety-nine cancer patients examined at the Section of Hematology/Oncology completed the MSAS-SF and the Functional Assessment Cancer Therapy (FACT-G). The Karnofsky performance status (KPS), extent of disease (EOD), and demographic data were assessed. The Cronbach alpha coefficient was used to assess internal reliability. MSAS-SF subscales were assessed against subscales of the FACT-G, the KPS, and EOD to determine criterion validity. Test–retest analysis was performed at 1 day and at 1 week. RESULTS The Cronbach alpha coefficients for the MSAS-SF subscales ranged from 0.76 to 0.87. The MSAS-SF subscales showed convergent validity with FACT subscales. Correlation coefficients were −0.74 (P < 0.001) for the PHYS and FACT-G physical well-being subscales, −0.68 (P < 0.001) for the PSYCH and FACT emotional well-being subscales, and −0.70 (P < 0.001) for GDI and FACT summary of quality-of-life subscales. The MSAS-SF subscales demonstrated convergent validity with performance status, inpatient status, and extent of disease. The test–retest correlation coefficients for the MSAS-SF subscales ranged from 0.86 to 0.94 at 1 day and from 0.40 to 0.84 for the 1 week group. CONCLUSIONS The MSAS-SF is a valid and easy to use instrument for Symptom Assessment. Cancer 2000;89:1162–71. Published 2000 American Cancer Society.
-
the memorial Symptom Assessment scale an instrument for the evaluation of Symptom prevalence characteristics and distress
European Journal of Cancer, 1994Co-Authors: Russell K. Portenoy, Howard T. Thaler, Alice B Kornblith, Mccarthy J Lepore, Hamutal Friedlanderklar, E Kiyasu, K Sobel, N Coyle, Nancy E Kemeny, Larry NortonAbstract:The Memorial Symptom Assessment Scale (MSAS) is a new patient-rated instrument that was developed to provide multidimensional information about a diverse group of common Symptoms. This study evaluated the reliability and validity of the MSAS in the cancer population. Randomly selected inpatients and outpatients (n = 246) with prostate, colon, breast or ovarian cancer were assessed using the MSAS and a battery of measures that independently evaluate phenomena related to quality of life. Symptom prevalence in the 218 evaluable patients ranged from 73.9% for lack of energy to 10.6% for difficulty swallowing. Based on a content analysis, three Symptoms were deleted and two were added; the revised scale evaluates 32 physical and psychological Symptoms. A factor analysis of variance yielded two factors that distinguished three major Symptom groups and several subgroups. The major groups comprised psychological Symptoms (PSYCH), high prevalence physical Symptoms (PHYS H), and low prevalence physical Symptoms (PHYS L). Internal consistency was high in the PHYS H and PSYCH groups (Cronback alpha coefficients of 0.88 and 0.83, respectively), and moderate in the PHYS L group (alpha = 0.58). Although the severity, frequency and distress dimensions were highly intercorrelated, canonical correlations and other analyses demonstrated that multidimensional Assessment (frequency and distress) augments information about the impact of Symptoms. High correlations with clinical status and quality of life measures support the validity of the MSAS and indicate the utility of several subscale scores, including PSYCH, PHYS, and a brief Global Distress Index. The MSAS is a reliable and valid instrument for the Assessment of Symptom prevalence, characteristics and distress. It provides a method for comprehensive Symptom Assessment that may be useful when information about Symptoms is desirable, such as clinical trials that incorporate quality of life measures or studies of Symptom epidemiology.
Richard Fielding - One of the best experts on this subject based on the ideXlab platform.
-
New insights in Symptom Assessment: the Chinese Versions of the Memorial Symptom Assessment Scale Short Form (MSAS-SF) and the Condensed MSAS (CMSAS).
Journal of pain and symptom management, 2008Co-Authors: Wendy W. T. Lam, Victor T. Chang, Chi Ching Law, Kh Wong, Richard FieldingAbstract:There are very few Symptom Assessment instruments in Chinese. We present the validity and reliability of the Memorial Symptom Assessment Scale Short Form (MSAS-SF) and the Condensed Form MSAS (CMSAS) in Chinese cancer patients. The Chinese version of the 32-item MSAS-SF, a self-report measure for assessing Symptom distress and frequency in cancer patients, was administered to 256 Chinese patients with colorectal cancer at a clinical oncology outpatient unit. Highly prevalent Symptoms included worrying (59%), dry mouth (54%), lack of energy (54%), feeling sad (48%), feeling irritable (48%), and pain (41%). Both the MSAS-SF and CMSAS demonstrated good validity and reliability. For the MSAS-SF subscales, Cronbach alphas ranged from 0.84 to 0.91, and for CMSAS subscales, from 0.79 to 0.87. Moderate-to-high correlations of MSAS-SF and CMSAS subscales with appropriate European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 subscales (0.42-0.71, Ps or =80% [P 4 [P
Joo-hyun Nam - One of the best experts on this subject based on the ideXlab platform.
-
Reliability and Validity of the Korean Memorial Symptom Assessment Scale-Short Form in Gynecological Cancer Patients.
Journal of pain and symptom management, 2017Co-Authors: Ju-hee Nho, Victor T. Chang, Sung Reul Kim, Joo-hyun NamAbstract:Abstract Context Symptoms of patients with cancer need to be evaluated with a standard instrument. The Memorial Symptom Assessment Scale-Short Form (MSAS-SF) is a Symptom Assessment tool that has been validated in many languages. Objectives The aim of the present study was to validate the Korean-version Memorial Symptom Assessment Scale—Short Form (MSAS-SF) in patients with gynecologic cancer. Methods We translated the MSAS-SF into Korean, and 175 gynecologic cancer inpatients completed the MSAS-SF, Functional Assessment Cancer Therapy—General (FACT-G), and gathered demographic and clinical data and Karnofsky Performance Status (KPS). Reliability was assessed for internal consistency with Cronbach's alpha coefficient. Pearson's correlation coefficient was calculated between the MSAS-SF and FACT-G subscales for convergent validity. T-test analysis was used to compare differences in MSAS-SF subscales by cancer stage and KPS for discriminant validity. Results The Cronbach's alpha coefficients for the MSAS-SF subscales ranged from 0.80 to 0.91. The Korean-version MSAS-SF subscales showed convergent validity with FACT-G subscales. The correlation coefficients were −0.640 (P Conclusion The Korean-version MSAS-SF is a valid tool for the reliable Assessment of patients with gynecologic cancer in Korea.
